Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04698031 · ClinicalTrials.gov registry record · Phase 4
Efficacy of Clopidogrel on Incidence of Silent Brain Infarction
A Phase 4 study of Silent Brain Infarction, sponsored by VA Office of Research and Development.
- Active
- Registry status
- Phase 4
- Development phase
- 134
- Enrollment target
- 1
- Study location
NCT04698031: Active Phase 4 study of Silent Brain Infarction, sponsored by VA Office of Research and Development.
NCT04698031 is a Phase 4 study of Silent Brain Infarction that is active but no longer recruiting, run by VA Office of Research and Development. The registered enrollment target is 134 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04698031, a Phase 4 study of Silent Brain Infarction, is active but no longer recruiting, sponsored by VA Office of Research and Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 134 participants
- Enrollment target
- 1
- Study location
Study Summary
Silent brain infarctions (SBIs) are a manifestation of covert cerebrovascular disease, without obvious clinical deficit, noted very often in patients presenting with a new stroke or new transient ischemic attack. SBIs are linked to a significant increase in risk for subsequent stroke and cognitive decline. However, no biomarker is currently available that can predict the recurrence of these subclinical lesions. Coated-platelets are a measure of platelet procoagulant potential significantly increased in patients with ischemic stroke or transient ischemic attack compared to unaffected controls. Higher coated-platelet levels are strongly associated with both the presence and number of SBIs. Among medications approved for preventing stroke recurrence, we identified clopidogrel as a pharmacological agent leading to a decrease in coated-platelet levels. In this project, we plan to evaluate if clopidogrel can decrease the rate of occurrence of new silent brain infarctions. The result will enhance the investigators understanding of the relationship between platelets and silent brain infarcts, leading to improved health care delivery and also potential targets for novel preventive pharmacological interventions.
Primary Outcome
Each of the two reviewers will independently adjudicate the presence, location and number of SBIs for each patient by reviewing both the initial and repeat scans at 24 months.
Conditions Studied
Interventions
- DRUG Clopidogrel treatment
- DRUG Aspirin treatment
Study Locations (1)
Oklahoma
- Oklahoma City VA Medical Center, Oklahoma City, OK - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2022-03-30 |
| Est. Completion | 2026-07-01 |
| Phase | Phase 4 |
What the registry record for NCT04698031 still lists
NCT04698031 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower).
The record links to 1 condition, with Silent Brain Infarction appearing as the primary indexed condition, and to 2 interventions - of which Clopidogrel treatment is the first listed.
NCT04698031 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT04698031 about?
NCT04698031 is a clinical study titled "Efficacy of Clopidogrel on Incidence of Silent Brain Infarction". Silent brain infarctions (SBIs) are a manifestation of covert cerebrovascular disease, without obvious clinical deficit, noted very often in patients presenting with a new stroke or new transient ischemic attack. SBIs are linked to a significant increase in risk for subsequent stroke and cognitive d...
What is the current status of trial NCT04698031?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 134 participants. The study started on 2022-03-30. Estimated completion is 2026-07-01.
What conditions does trial NCT04698031 study?
This clinical trial studies the following conditions: Silent Brain Infarction.
What interventions are being tested in trial NCT04698031?
The interventions under investigation include: Clopidogrel treatment (DRUG), Aspirin treatment (DRUG).
Who is sponsoring clinical trial NCT04698031?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04698031 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04698031's enrollment target sits among peer trials
134 606th of 2000 higher than 1,392 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI